Drugwatch.com is excited to announce the addition of three respected health care professionals to our network of expert contributors.
Along with Drugwatch’s other highly-qualified medical and legal experts, these individuals will help us ensure that the information we provide is high quality, accurate, up-to-date and presented in a way that is easy for our readers to understand.
Our network of experts includes award-winning legal professionals, renowned medical practitioners, and patient advocates who share Drugwatch’s mission to provide trustworthy, current information. Drugwatch vets each expert with criteria in the following areas: education, formal training, credentials, membership in professional societies, objectivity and reputation with clients and peers.
We are pleased to welcome Drs. Carl V. Crawford, Hooman Noorchasm and Diana Zuckerman as our newest experts on Drugwatch.
Carl V. Crawford, Jr., M.D.
Gastroenterologist and hematologist Dr. Carl V. Crawford, Jr. is an assistant professor of clinical medicine and attending physician at New York Presbyterian-Weill Cornell Medicine in the Division of Gastroenterology and Hepatology. In addition to general gastroenterology he is a GI specialist working with critically ill and bone marrow transplant patients. He is also involved in a number of C. difficile-related clinical trials and original outcomes research.
Dr. Crawford is a member of the American College of Gastroenterology, the American Gastroenterological Association, and the American and New York Society of Gastrointestinal Endoscopy.
Crawford joined Drugwatch’s network of experts to help us close gaps in health care education.
“It should be a priority for trusted sources to describe medical related issues in a way that the general population can understand,” said Crawford. “I appreciate that Drugwatch requests reviews from professionals within their areas of expertise to ensure that their pieces are accurate before publishing. The articles I have reviewed are a good introduction to common GI illnesses and I would recommend this to anyone who may be interested in what can happen to their body.”
Hooman Noorchasm, M.D., PhD
Cardiothoracic surgeon Dr. Hooman Noorchashm is a physician-scientist who advocates for patient safety and ethics in medicine. His faculty appointments have included positions at University of Pennsylvania School of Medicine, Harvard Medical School, Thomas Jefferson University Hospital and the Philadelphia VA Hospital.
He has authored articles in peer-reviewed medical journals, medical books chapters and has lectured at several conferences and acquired research grants from National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases.
Noorchashm shares Drugwatch’s passion for providing unbiased, fact-based information to health care consumers.
“Drugwatch not only provides incisive journalism on key healthcare topics affecting citizens’ everyday lives, more importantly, it is not beholden to any particular corporate interest. I think this commitment to clear-sighted truth telling is absolutely necessary for health care consumers to make cogent decisions and self-advocate well,” Noorchashm said.
Diana Zuckerman, PhD
Health policy expert Dr. Diana Zuckerman is the president of National Center for Health Research, a nonprofit that conducts and analyzes health research and focuses on the safety of medical and consumer products. Before founding NCHR, Zuckerman’s previously worked as a scientist and advocate in academia, the U.S. Congress, the White House, the U.S. Department of Health and Human Services, and at nonprofit organizations.
Drugwatch has worked with NCHR in its efforts to make health care research understandable for the public, including assisting with NCHR workshops for health care reporters and press teleconferences to present the latest COVID-19 research.
“Drugwatch is a great source of information for patients and providers who care about the safety and effectiveness of all kinds of medical products. We’ve been glad to partner with them in our mutual efforts to get that essential information to the people who need it most,” Zuckerman said.
Share This Page: